JAK1-IN-18
JAK1-IN-18 (Example 2) is a selective JAK1 inhibitor with an IC50 of 0.15 nM for JAK1 over JAK2 and JAK3. JAK1-IN-18 significantly reduces inflammation in DSS -induced ulcerative colitis (UC) mouse models and DNBS (HY-W324435) -induced Crohn's disease (CD) rat models. JAK1-IN-18 can be used for autoimmune diseases (such as inflammatory bowel disease), viral infections (such as HBV infection) and cancers (such as blood cancer) research[1].
Product Specifications
CAS Number
2459377-98-9
UNSPSC
12352005
Target
JAK
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection; Inflammation/Immunology
Smiles
O=C(NCC(F)F)[C@@H]1CN(CCC1)NC2=C3C(NC=C3)=NC=C2C(N)=O
Molecular Formula
C16H20F2N6O2
Molecular Weight
366.37
References & Citations
[1]Wu Y, et al. Janus kinase (jak) family inhibitor, preparation of same, and applications thereof. WO2020156271A1. 2020-08-06.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3; Tyk2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
